Conditions: Metastatic Melanoma; Melanoma Brain Metastasis
Interventions: Device: NovoTTF-200A; Drug: Pembrolizumab
Sponsors: Brown University; NovoCure Ltd.
Not yet recruiting
Feeds
16576 items (16576 unread) in 74 feeds
Acinar Cell Carcinoma
(259 unread)
Acinic Cell Carcinoma
(153 unread)
Adenoid Cystic Carcinoma
(266 unread)
Adrenal Gland Cancer
(1205 unread)
Ampulla Of Vater
(258 unread)
Anal Cancer
(1225 unread)
Angiosarcoma
(494 unread)
Appendix Cancer
(361 unread)
Bile Duct Cancer
(2223 unread)
Brain and CNS
(3429 unread)
Carcinoid
(435 unread)
Endocrine/Neuroendocrine
(2668 unread)
Gall Bladder Cancer
(644 unread)
Hemangioendothelioma
(533 unread)
Hepatoblastoma
(396 unread)
Pancreas
(266 unread)
Phyllodes
(157 unread)
PMP and Mucinous Tumors
(217 unread)
Rhabdomyosarcoma
(562 unread)
Sarcoma
(825 unread)
Trial - Neuroendocrine Cancers (2 unread)
-
NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis
Posted: October 16th, 2019, 2:00am GMT
-
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma
Posted: October 8th, 2019, 2:00am GMT
Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8; IL13RA2 Positive; Metastatic Melanoma; Cutaneous Melanoma, Stage III; Cutaneous Melanoma, Stage IV; Melanoma; Uveal Melanoma; Acral Melanoma; Neuroendocrine Tumors; Paraganglioma; Adrenocortical Carcinoma; Pancreatic Neuroendocrine Tumor; Thyroid Cancer; Breast Cancer; Lung Adenocarcinoma; Head and Neck Squamous Cell Carcinoma
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine Phosphate; Biological: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells; Drug: Recombinant Interleukin-2
Sponsors: Jonsson Comprehensive Cancer Center; City of Hope National Medical Center
Recruiting